权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Control of Chromosome Segregation by DNA Topoisomerase II

DNA 拓扑异构酶 II 控制染色体分离

基本信息

批准号：
10324569
负责人：
DUNCAN J. CLARKE
金额：
$ 29.29万
依托单位：
UNIVERSITY OF MINNESOTA
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-03-01 至 2023-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10324569
关键词：
Advanced Development Anaphase Aneuploidy Area Binding Biochemical C-terminal Cancer Etiology Catalytic Domain Cell Cycle Cell Cycle Regulation Cell division Cells Chromatids Chromosome Segregation Chromosomes Complex Congenital Abnormality DNA DNA Damage DNA biosynthesis Data Defect Drug Targeting Ensure Enzymes Failure Feeds Functional disorder Genetic Genome Genomic Instability Genomics Human Kinetochores Light Link Locales Malignant Neoplasms Mechanics Microtubules Mitosis Mitotic Mitotic Cell Cycle Mitotic Spindle Apparatus Modeling Molecular Molecular Conformation Monitor Nuclear Pore Complex Outcome Study Pathway interactions Phase Population Positioning Attribute Process Production Reaction Regulation Role SHPS-1 protein Signal Transduction Signaling Molecule Signaling Protein Sister Chromatid Site Therapeutic Topoisomerase II Topoisomerase II inhibition Translational Research Yeasts biochemical tools cancer therapy daughter cell developmental disease genetic approach insight mutant novel protein protein interaction public health relevance recruit response scaffold segregation therapeutic target tool transmission process treatment strategy

项目摘要

Abstract Chromosome segregation errors result in aneuploidy which causes birth defects and cancer. We have defined a new mitotic Topo II-responsive control (TRC) in yeast that delays the cell cycle when Topo II activity is insufficient for accurate chromosome segregation. This TRC mechanism is conserved in human cells, but has not been extensively studied. Activation of the TRC is triggered by defects in the strand passage reaction of Topo II, when the enzyme transits too slowly through its structural conformations. TRC activation also requires the catalytically inert C-terminal domain of Topo II, which contains novel protein- protein interaction motifs that bind to TRC signaling proteins. The central model is that aberrant strand passage may structurally transfer from the catalytic core of Topo II to the C-terminal domain which functions as a signal-generating scaffold to halt the cell cycle. The conservation between the human and yeast TRC responses provides unique opportunities to identify the TRC components and to reveal the mechanism of TRC activation. We aim to determine the cellular/genomic sites of TRC activation, the signaling molecules involved and the mechanism of TRC activation by the C-terminal domain of Topo II. The results of these studies will impact opportunities for translational research because we will identify new potential therapeutic targets. Our findings will also impact the use of widely prescribed therapeutic drugs that target Topo II because we will gain mechanistic insight into cellular responses to Topo II inhibition. The preliminary data and newly developed experimental tools place us in a unique position to determine the conserved mechanism of this scarcely studied mitotic control.

摘要